AIM
SRPT icon

Arcadia Investment Management’s Sarepta Therapeutics SRPT Stock Holding History

Arcadia Investment Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$60.9K Sell
2,800
-880
-24% -$17K 0.01% 169
2025
Q4 		$79.2K Sell
3,680
-300
-8% -$6.32K 0.01% 162
2025
Q3 		$76.7K Sell
3,980
-200
-5% -$3.56K 0.01% 167
2025
Q2 		$71.5K Sell
4,180
-3,635
-47% -$155K 0.01% 171
2025
Q1 		$499K Buy
7,815
+880
+13% +$92.6K 0.09% 90
2024
Q4 		$843K Buy
+6,935
New +$850K 0.13% 76

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arcadia Investment Management's SRPT Position: Q1 2026 in Review

Arcadia Investment Management reduced its Sarepta Therapeutics (SRPT) stake by 24% in Q1 2026, selling an estimated $17K and leaving 2,800 shares worth $60.9K. The position accounts for 0.01% of the portfolio, ranked #169.

Arcadia Investment Management first reported a position in SRPT in Q4 2024 and has held it in 6 quarters since. The position peaked at $843K in Q4 2024. 344 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Arcadia Investment Management held 2,800 shares of Sarepta Therapeutics worth $60.9K as of Q1 2026.
  • Arcadia Investment Management sold 880 Sarepta Therapeutics shares in Q1 2026, an estimated $17K.
  • Sarepta Therapeutics made up 0.01% of Arcadia Investment Management's portfolio in Q1 2026, its #169 holding.
  • Arcadia Investment Management first reported a position in Sarepta Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Arcadia Investment Management's Sarepta Therapeutics position peaked at $843K in Q4 2024.
  • 344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Arcadia Investment Management's 13F filing for Q1 2026, filed 22 Apr 2026.